At a Glance
Your Trusted CDMO Partner
-
Global Clients
100+
-
Employees
4,400+
-
Global Regulatory
Approvals
-
Total Capacity
604KL + Plant 5 *
Plant 1
30,000L
Plant 2
154,000L
Plant 3
180,000L
Plant 4
240,000L
Plant 5
180,000L*
* To be operational in April 2025
- Awards
-
By consistently delivering superior client satisfaction through execution excellence and innovation, Samsung Biologics has been selected by our clients for the CDMO Leadership Awards for ten consecutive years.
- CDMO LEADERSHIP AWARDS 2023
-
CDMO LEADERSHIP AWARDS 2023 CAPABILITIES
CDMO LEADERSHIP AWARDS 2023 COMPATIBILITY
CDMO LEADERSHIP AWARDS 2023 EXPERTISE
CDMO LEADERSHIP AWARDS 2023 QUALITY
CDMO LEADERSHIP AWARDS 2023 RELIABILITY
CDMO LEADERSHIP AWARDS 2023 SERVICE
Samsung Biologics received additional recognition as “Champion” in the Capabilities, Compatibility, Quality, and Reliability categories
recognition as “Champion” in the
Capabilities, Compatibility, Quality, and
Reliability categories
CDMO LEADERSHIP AWARDS 2023 CAPABILITIES
CDMO LEADERSHIP AWARDS 2023 COMPATIBILITY
CDMO LEADERSHIP AWARDS 2023 EXPERTISE
CDMO LEADERSHIP AWARDS 2023 QUALITY
CDMO LEADERSHIP AWARDS 2023 RELIABILITY
CDMO LEADERSHIP AWARDS 2023 SERVICE
Global Regulatory Approvals
- 2015
-
FDA : 1
Total : 1
- 2016
-
EMA : 4
FDA : 3
Total : 7
- 2017
-
Others : 4
EMA : 5
FDA : 4
Total : 13
- 2018
-
Others : 8
EMA : 7
FDA : 8
Total : 23
- 2019
-
Others : 37
EMA : 12
FDA : 9
Total : 58
- 2020
-
Others : 63
EMA : 15
FDA : 15
Total : 93
- 2021
-
Others : 100
PMDA : 0
EMA : 19
FDA : 18
Total : 137
- 2022
-
Others : 153
EMA : 25
FDA : 25
Total : 203
- 2023
-
Others : 206
EMA : 32
FDA : 30
Total : 268
Number of Approvals | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|
FDA | 1 | 3 | 4 | 8 | 9 | 15 | 18 | 25 | 30 |
EMA | 4 | 5 | 7 | 12 | 15 | 19 | 25 | 32 | |
Others (PMDA, MFDS, and etc.) |
4 | 8 | 37 | 63 | 100 | 153 | 206 | ||
Cumulative Total | 1 | 7 | 13 | 23 | 58 | 93 | 137 | 203 | 268 |